摘要
目的探讨阻塞性睡眠呼吸暂停低通气综合征(OSAHS)患者血清脂蛋白(a)[Lp(a)]和心肌肌钙蛋白I(cTnI)的变化及经鼻持续气道正压通气(nCPAP)对其影响。方法 OSAHS组(32例)和正常对照组(30例)均经多导睡眠图(PSG)监测,并空腹抽取静脉血。将OSAHS患者血脂中的Lp(a)、cTnI与正常对照组进行比较。OSAHS患者经nCPAP治疗4周后,对其治疗前后的相应指标做出比较。结果 OSAHS患者Lp(a)水平显著高于健康查体人群(t=3.184,P<0.01),OSAHS患者nCPAP治疗后比治疗前Lp(a)水平显著下降(t=3.117,P<0.01);OSAHS患者cTnI水平显著高于健康查体人群(t=6.915,P<0.01),OSAHS患者nCPAP治疗后比治疗前cTnI水平显著下降(t=6.521,P<0.01)。结论 OSAHS患者患动脉粥样硬化和血栓栓塞性心血管疾病的倾向显著增强,Lp(a)水平可作为OSAHS心血管功能病变的早期预测指标;重度OSAHS的心肌受到不同程度的损伤,cTnI水平可作为OSAHS心肌损伤的客观指标;nCPAP治疗可有效逆转上述病变。
Objective To investigate the changes of lipoprotein（a） [ Lp（a） ] and cardiac troponin Ⅰ（cTnⅠ） in patients with obstructive sleep apnea - hypopnea syndrome before and after institution of nasal continuous positive airway pressure（nCPAP）. Methods OSAHS group（32 cases） and the normal control group（30 cases） have been more polysomnography（PSG） monitoring,and fasting blood collected. OSAHS will be in patients with blood lipid Lp（a） , cTnI and the normal control group for comparison. OSAHS patients with continuous positive airway pressure（nCPAP） for four weeks, before and after their treatment compared to the corresponding indicators. Results OSAHS patients＇ Lp（a） levels was significantly higher than that of population heahh checkup（ t = 3. 184, P 〈 0.01）, nCPAP treatment in patients with OSAttS compared with Lp （a） levels before treatment decreased significantly （t = 3. 117, P 〈 0. 01 ） ; OSAHS patients＇ cTnl levels was significantly higher than that of population heahh eheckup（ t =6. 915 ,P 〈0. 01） ,nCPAP treatmenl in patients with OSAIIS compared with cTnl levels before treatment decreased significantly （t = 6. 521 ,P 〈 0.01 ）. Conclusion OSAHS patients suffering from atheroscle,sclerosis and thrombombolic cardiovascular diseases tend to significantly improve, Lp（a） levels can be used as OSAHS cardiovascular disease in the early forecast indicators;OSAHS myocardial are subject to different degrees of injury, cTnl levels can be used as OSAtfS myocardial injury objective indicators; nCPAP treatment can effectively reverse the disease.
出处
《中国医学创新》
CAS
2009年第36期1-3,共3页
Medical Innovation of China
